| answer text |
<p>The National Institute for Health and Care Excellence (NICE) has advised that it
has not made any assessment of the need to develop a clinical guideline on the care
of people with hidradenitis suppurativa, nor has it been asked to develop a clinical
guideline on this condition.</p><p> </p><p>NICE published technology appraisal guidance
on adalimumab (Humira) for treating moderate to severe hidradenitis suppurativa (TA392)
on 22 June 2016<em>,</em> which recommends its use. Commissioners now have three months
in which to put in place funding arrangements.</p>
|
 |
